Join a panel of experts including Donna Ryan, MD, Anthony Auriemma, MD, and Dana Trippi, DO, for a discussion on obesity medicine and the need for clinicians to adopt a comprehensive, individualized approach to patient care.
Join a panel of experts including Donna Ryan, MD, Professor Emerita at the Pennington Biomedical Research Center in Baton Rouge, Louisiana; Anthony Auriemma, MD, Medical Director at Ascension Illinois Medical Group Weight Loss Solutions in Schaumburg, Illinois; and Dana Trippi, DO, Founder and Chief Medical Officer at Premier Physicians Weight Loss and Wellness in Las Vegas, Nevada, for a discussion on anti-obesity medicine and the need for clinicians to adopt a comprehensive, individualized approach to patient care. The panel will also review data from a cardiovascular outcomes trial of a glucagon- like peptide-1 receptor agonist (GLP-1 RA) in adults with obesity or overweight and established cardiovascular disease.
Additionally, results from along-term weight management trial will be reviewed, including data on sustained body weight reduction at 2 years, as well as effects on cardiometabolic risk factors.
Please see Prescribing Information, including boxed warning.
This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.
The moderator and expert discussants were compensated by Novo Nordisk for their participation in this podcast.
Faculty Presenters:
Donna Ryan, MD
Professor Emerita
Pennington Biomedical Research Center
Baton Rouge, LA
Anthony Auriemma, MD, JD, FOMA
Market Medical Director and Vice President of Clinical Partnerships
knownwell
Schaumburg, IL
Dana Trippi, D.O., ABEM, DABOM
Founder/Chief Medical Officer
Premier Physicians Weight Loss &Wellness
Las Vegas, NV